ABLIM3

Across TCGA pan-cancer cohorts, ABLIM3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABLIM3 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ABLIM3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABLIM3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where ABLIM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.485	0.996	.001	31	view →
LSCC	DFS	Quartile	II,III,IV	0.813	1.000	.014	14	view →
CCRCC	DFS	Quartile	II,III,IV	0.856	0.123	.036	9	view →
PDAC	OS	Tertile	IV	0.468	0.962	.038	6	view →
HNSC	DFS	Median	IV	0.798	0.559	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABLIM3–LUAD (DFS)

Open the LUAD breakdown →